ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode is combining RNA therapies with an organ-specific lipid nanoparticle delivery system

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.

The company was formed through a merger between the original ReCode Therapeutics and TranscripTx Inc. earlier this month. MPM Capital, Vida Ventures, Hunt Technology Ventures and Osage University Partners also participated in the oversubscribed round.

The original ReCode was developing a transfer RNA (tRNA) therapy for cystic fibrosis (CF) and an

Read the full 804 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE